Current stock page

Catalysts

TSHA Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

TSHATaysha Gene Therapies, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 5/10
$4.10−$0.11 (−2.61%)

Latest quote

  • Momentum
    32
  • Value
    —
  • Quality
    37
  • Risk resilience
    37
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 3, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 35/100

Momentum 32/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 23.72%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 32/100AIQ Edge 5/10 In Line With Peers
Beat rate
38%
3 of 8 reported periods
Average surprise
-0.2%
Across covered historical reports
Latest result
+22.2%
Nov 12, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 12, 2026—-$0.13-$0.10+22.2%$755.56K—
Aug 11, 2026—-$0.11-$0.13-14.8%$680K—
May 6, 2026—-$0.10-$0.12-20.0%$755.56K—
Mar 19, 2026—-$0.11-$0.08+27.3%$2.24M$5.48M
Nov 4, 2025—-$0.09-$0.09+0.0%$1.89M—
Aug 12, 2025—-$0.07-$0.09-28.6%$1.73M$1.99M
May 15, 2025—-$0.08-$0.08+0.0%$1.08M$2.3M
Feb 26, 2025—-$0.08-$0.07+12.5%$2.05M$2.02M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
13
Buy
12-month analyst target
—
— versus current price
Based on 13 analyst observations. Targets are estimates, not predictions.
No analyst target path in this snapshot.
Low target
—
—
Average target
—
—
High target
—
—

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 3, 2027

Next known earnings or reporting date.

EPS estimate-$0.11

Current analyst expectation for the upcoming report.

Revenue estimate$1.59M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score32

Where event reaction would show up first.

AIQ score35/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
13

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
seekingalpha.com · Nov 12, 2026

Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript

Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call November 12, 2026 8:30 AM ESTCompany ParticipantsSean Nolan - CEO & ChairmanSukumar Nagendran -...

gurufocus.com · Nov 12, 2026

Q3 2026 Taysha Gene Therapies, Inc. Earnings Call Transcript

Nov 12, 2026 / 01:30PM GMTOperator (audio in progress) (Operator Instructions) I would now like to hand the call over to Stephanie Webster. Please go ahead.Step

manilatimes.net · Nov 6, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 2, 2026, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, restricted stock units (RSUs) representing 25,000 shares of the Company’s common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

gurufocus.com · Sep 17, 2026

TSHA Initiates Coverage On Wolfe Research -- Rating Set to Outperform

Taysha Gene Therapies (TSHA) Analyst Rating Update On September 17, 2026, Taysha Gene Therapies (TSHA) received an 'Outperform' rating from Wolfe Research. N

manilatimes.net · Sep 4, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Open full news and sentiment

TSHA Catalysts FAQ

What are the next catalysts for TSHA stock?

TSHA's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move TSHA stock?

Upcoming events that could move TSHA include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could TSHA's next earnings report affect the stock?

TSHA's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive TSHA stock higher?

TSHA could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt TSHA stock?

TSHA could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.